Hosted by the US Environmental Protection Agency
EPA is prioritizing ongoing efforts to develop and use New Approach Methods (NAMs) to test chemicals for health effects. This presentation will provide an overview of Agency efforts to use NAMs to inform health assessments. This presentation will also introduce the new EPA Transcriptomics Assessment Product designed to address important gaps and target chemicals lacking traditional toxicity testing data.
EPA ORD researchers leverage a variety of data streams to meet the needs of users. However, assessment products offered to date have relied on availability of existing toxicity testing data. Of the numerous chemicals that permeate our lives, only a small proportion have traditional toxicity testing data to inform health assessments. To provide actionable data for chemicals lacking traditional testing information, EPA ORD has developed a new human health assessment product—ETAP. The EPA Transcriptomic Assessment Product (ETAP) takes advantage of novel advances in gene expression analysis to determine dose-response relationships. ETAPs are one assessment product within the portfolio that provide data values for use by states and others in months instead of years. EPA released its first ETAP for Perfluoro-3-Methoxypropanoic Acid ("MOPA") earlier this year.